A Phase II Multicenter, Open-label, Randomized, Parrallel Group Study to Assess the Pharmacokinetics of Bevirimat (BVM) 100 mg Tablets Administered to HIV-1 Positive Patients for 15 Days.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Bevirimat (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Myrexis
- 06 Apr 2010 New trial record